E. Läwitz

1.6k total citations
59 papers, 1.1k citations indexed

About

E. Läwitz is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, E. Läwitz has authored 59 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hepatology, 32 papers in Epidemiology and 17 papers in Immunology. Recurrent topics in E. Läwitz's work include Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (17 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). E. Läwitz is often cited by papers focused on Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (17 papers) and Immunodeficiency and Autoimmune Disorders (16 papers). E. Läwitz collaborates with scholars based in United States, Germany and Canada. E. Läwitz's co-authors include M. Rodríguez‐Torres, Ira M. Jacobson, F. Poordad, Mark Sulkowski, William T. Symonds, K.V. Kowdley, Barry Bernstein, Thomas Podsadecki, M. Michelle Berrey and John G. McHutchison and has published in prestigious journals such as Journal of Hepatology.

In The Last Decade

E. Läwitz

59 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Läwitz United States	22	1.0k	939	339	104	94	59	1.1k
Isla Humphreys United Kingdom	8	1.4k 1.4×	1.3k 1.4×	266 0.8×	65 0.6×	132 1.4×	11	1.6k
Dessislava I. Dimitrova United States	8	688 0.7×	588 0.6×	161 0.5×	74 0.7×	67 0.7×	11	775
Ewa Janczewska Poland	13	718 0.7×	713 0.8×	146 0.4×	54 0.5×	64 0.7×	68	860
Etsuko Iio Japan	17	584 0.6×	626 0.7×	144 0.4×	53 0.5×	190 2.0×	52	842
Yoshiyuki Suzuki Japan	9	797 0.8×	784 0.8×	173 0.5×	49 0.5×	45 0.5×	20	1.0k
Y‐F Liaw Taiwan	12	648 0.6×	583 0.6×	62 0.2×	84 0.8×	65 0.7×	20	840
Vincent Leroy France	17	828 0.8×	813 0.9×	82 0.2×	34 0.3×	49 0.5×	37	1.1k
Agostino Cividini Italy	16	993 0.9×	859 0.9×	66 0.2×	134 1.3×	81 0.9×	31	1.2k
Hiromitsu Kumada Japan	8	847 0.8×	810 0.9×	60 0.2×	92 0.9×	53 0.6×	15	938
Antonio Madejón Spain	18	524 0.5×	492 0.5×	167 0.5×	20 0.2×	69 0.7×	35	678

Countries citing papers authored by E. Läwitz

Since Specialization

Citations

This map shows the geographic impact of E. Läwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Läwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Läwitz more than expected).

Fields of papers citing papers by E. Läwitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Läwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Läwitz. The network helps show where E. Läwitz may publish in the future.

Co-authorship network of co-authors of E. Läwitz

This figure shows the co-authorship network connecting the top 25 collaborators of E. Läwitz. A scholar is included among the top collaborators of E. Läwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Läwitz. E. Läwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Younossi, Zobair M., Maria Stepanova, Lynn H. Gerber, et al.. (2018). The impact of sustained virologic response on severe fatigue in patients with chronic hepatitis C: The role of HCV viremia and co-morbidities. Journal of Hepatology. 68. S531–S531. 2 indexed citations

Nelson, David R., Daniel Bernstein, B. Freilich, et al.. (2015). P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study. Journal of Hepatology. 62. S624–S624. 9 indexed citations

Kowdley, Kris V., B. Bacon, Doug Dieterich, et al.. (2015). P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network. Journal of Hepatology. 62. S665–S666. 1 indexed citations

Läwitz, E., Christophe Hézode, Edward Gane, et al.. (2014). O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY. Journal of Hepatology. 60(1). S25–S26. 20 indexed citations

Muir, Andrew J., John M. Hill, E. Läwitz, et al.. (2013). 876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS. Journal of Hepatology. 58. S360–S360. 9 indexed citations

Kowdley, K.V., E. Läwitz, F. Poordad, et al.. (2013). 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY. Journal of Hepatology. 58. S2–S2. 47 indexed citations

Reesink, Hendrik W., Stefan Zeuzem, E. Läwitz, et al.. (2012). 58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION. Journal of Hepatology. 56. S26–S26. 45 indexed citations

Lok, A.S., David Gardiner, Christophe Hézode, et al.. (2012). 1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS. Journal of Hepatology. 56. S557–S557. 12 indexed citations

Sulkowski, Mark, M. Rodríguez‐Torres, E. Läwitz, et al.. (2012). 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS. Journal of Hepatology. 56. S560–S560. 37 indexed citations

10.

Tatum, H., Paul J. Thuluvath, E. Läwitz, et al.. (2012). 1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION. Journal of Hepatology. 56. S460–S460. 4 indexed citations

11.

Läwitz, E., Fred Poordad, Rajeev Menon, et al.. (2011). 1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS. Journal of Hepatology. 54. S482–S482. 6 indexed citations

12.

Jacobson, Ira M., Paul J. Pockros, Jacob Lalezari, et al.. (2010). 2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS. Journal of Hepatology. 52. S465–S465. 18 indexed citations

13.

Rodríguez‐Torres, M., E. Läwitz, Barbara R. Conway, et al.. (2010). 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS. Journal of Hepatology. 52. S14–S14. 26 indexed citations

14.

Läwitz, E., Vinod K. Rustgi, Tarek Hassanein, et al.. (2010). 2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S467–S467. 34 indexed citations

15.

Zeuzem, Stefan, Mark Sulkowski, E. Läwitz, et al.. (2009). 1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS. Journal of Hepatology. 50. S377–S377. 13 indexed citations

16.

Jacobson, Ira M., Paul J. Pockros, Jacob Lalezari, et al.. (2009). 1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1. Journal of Hepatology. 50. S382–S383. 32 indexed citations

17.

Sulkowski, Mark, E. Läwitz, M. Shiffman, et al.. (2008). 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY. Journal of Hepatology. 48. S370–S371. 29 indexed citations

18.

Poordad, F., et al.. (2008). 996 TREATMENT WEEK 12 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAIVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS. Journal of Hepatology. 48. S373–S373. 7 indexed citations

19.

Ghalib, R., E. Läwitz, B. Freilich, et al.. (2007). [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA. Journal of Hepatology. 46. S245–S246. 7 indexed citations

20.

Afdhal, Nezam H., Claire O’Brien, Eliot Godofsky, et al.. (2007). [6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS. Journal of Hepatology. 46. S5–S5. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact